Developer docs
API playgroundTry for free, no card

Search company profiles

Macleods Pharmaceuticals Ltd.

Full company profile

uuid000dfir

Namestring
Macleods Pharmaceuticals Ltd.
Legal namestring
Macleods Pharmaceuticals Ltd.
Company typeenum
Private
Founded yearint
1989
Descriptiontext

Macleods Pharmaceuticals Ltd. is a privately held, vertically integrated Indian pharmaceutical company headquartered in Mumbai that develops, manufactures, and markets generic medicines across more than 19 therapeutic categories, including anti-tuberculosis drugs, antiretrovirals, anti-infectives, cardiovascular, central nervous system, diabetology, oncology, and peptides. The company operates its own active pharmaceutical ingredient (API) and formulations development facilities, supported by a 250-bed bioequivalence centre equipped with NABL-accredited clinical laboratories, 20 LC/MS/MS instruments, and SAS-based statistical analysis for crossover, replicate, parallel, and steady-state bioequivalence studies. Manufacturing facilities are inspected and approved by USFDA, WHO Geneva, UK MHRA, and ANVISA, with 185 ANDAs filed and 100 approved at the USFDA as of August 2023 and WHO prequalified medicines in the portfolio.

Macleods distributes products in over 170 countries through a mix of wholly-owned subsidiaries (USA, UK, Germany, Spain, South Africa, Ukraine, Kazakhstan, Malaysia, Philippines, and Nigeria), branch offices, a joint venture in Indonesia (PT Sampharindo Retroviral Indonesia, established 2017), and out-licensing arrangements with European distributors. Its customer base spans government health programmes such as India's National TB Elimination Programme and the Global Drug Facility, public healthcare systems, private hospitals and pharmacies, and institutional procurement channels. Direct field sales forces call on physicians, specialists, hospitals, and pharmacies across multiple markets, supplemented by participation in medical congresses and direct healthcare-professional communications.

Revenue is generated predominantly through one-time sales of generic pharmaceutical products across both regulated (US, UK, EU) and emerging (South Africa, MENA, CIS, Southeast Asia) markets, with pricing not publicly disclosed. The company has scaled through retained earnings rather than external funding, with 18,000+ employees globally. Notable recent strategic activity includes entry into the South Africa private sector (November 2022), a February 2026 Delhi High Court ruling favorable to Macleods in a Linagliptin patent challenge, and the appointment of a new group CFO in February 2026. The founder, Dr. Rajendra Agarwal, continues as Managing Director.

Short descriptiontext

Macleods Pharmaceuticals Ltd. is a privately held, vertically integrated Indian generic pharmaceutical company that develops, manufactures, and distributes medicines across 19+ therapeutic areas to public health programmes, hospitals, and pharmacies in 170+ countries through subsidiaries and out-licensing partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceutical manufacturing, active pharmaceutical ingredients, bioequivalence studies, antiretroviral medications, anti-tuberculosis drugs
Industry3 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Pharmaceutical Products
TypeOne Time License
Description

Revenue generated from manufacturing and selling generic pharmaceutical formulations across multiple therapeutic categories including anti-TB, ARVs, cardiovascular, anti-infectives, CNS, diabetology, oncology, and other treatments. Products are sold in over 170 countries globally through direct presence in multiple markets.

macleodspharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Simarax
Description

Sildenafil 50 mg film-coated tablets for erectile dysfunction, marketed in the UK market.

macleodspharma.com
Core offering1 text field

Macleods Pharmaceuticals Ltd. is a vertically integrated global pharmaceutical manufacturer that develops, produces, and sells generic formulations and Active Pharmaceutical Ingredients (APIs) across more than 19 therapeutic categories including anti-tuberculosis, antiretrovirals, cardiovascular, central nervous system, diabetology, anti-infectives, anti-malarials, oncology, and peptides. The company operates R&D, bioanalytical and 250-bed bioequivalence centres, and manufactures products at facilities approved by USFDA, WHO Geneva, UK MHRA, and ANVISA, supplying generic medicines through direct subsidiaries, field sales, and out-licensing distributors in over 170 countries.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Macleods Pharmaceuticals Ltd. is a vertically integrated global pharmaceutical organization and one of the top 10 companies in the Indian pharmaceutical market. The company provides generic pharmaceutical products across multiple therapeutic areas including Anti-Infectives, Anti-Virals, Anti-Retrovirals (ARVs), Blood Related, Cardiology, Central Nervous System, Diabetology, Endocrinology, Gastroenterology, Pain Management, Respiratory, Urology, Anti-Tuberculosis (Adult and Pediatric), Anti-Malaria, Oncology, and Peptides. The company operates R&D and bioequivalence centers with 250 beds, manufactures Active Pharmaceutical Ingredients (APIs) and formulations, and distributes products globally through subsidiaries and offices in India, USA, UK, Germany, Spain, South Africa, Kazakhstan, Ukraine, Indonesia, MENA region, and the Philippines. The product portfolio includes branded generics like Rivaroxaban, Apixaban, Simarax, and Emtricitabine/Tenofovir, as well as extensive generic formulations across all therapeutic categories.

Product and service9 records
1USA Generic Pharmaceutical Product Portfolio
CategoryGeneric Pharmaceuticals - US Market
Description

Generic pharmaceutical formulations distributed in the United States market across cardiovascular, central nervous system, anti-infective, and respiratory therapeutic categories, including products such as Acyclovir Ointment, Amlodipine/Olmesartan tablets, and Aripiprazole tablets. Marketed through Macleods Pharma USA Limited. As of August 31, 2023, Macleods had 185 ANDAs filed with USFDA, of which 100 were approved.

2MENA Generic Pharmaceutical Product Portfolio
CategoryGeneric Pharmaceuticals - MENA Market
Description

Generic pharmaceutical products for Middle East and North Africa markets covering Anti-Infectives, Anti-Virals, Anti-Retrovirals, Blood Related, Cardiology, CNS, Diabetology, Endocrinology, Gastroenterology, Pain Management, Respiratory, Urology, Anti-Tuberculosis (Adult and Pediatric), Anti-Malaria, Oncology, and Peptides. Distributed through Macleods' MENA operations across Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Jordan, Lebanon, Syria, Israel, Egypt, and other regional markets.

3Kazakhstan Generic Pharmaceutical Product Portfolio
CategoryGeneric Pharmaceuticals - Kazakhstan Market
Description

Products registered in Kazakhstan including Mucogen, Trimspa, Rabemac, Nupenta, Valmac, Clopi-75, Mucitus, Rapitus, and Zithrox-Macleods, spanning gastroenterology, cardiology, pulmonology, and infections. Distributed through Macleods Pharma Kazakhstan branch office with over 100 employees across major cities and regions.

4Rivaroxaban generic anticoagulant
CategoryCardiology / Anticoagulant Generic
Description

Generic anticoagulant equivalent to Bayer's Xarelto, available in 2.5mg, 10mg, 15mg, and 20mg film-coated tablets for Germany and MENA markets. Used for the prevention and treatment of thromboembolic disorders.

5Apixaban generic anticoagulant
CategoryCardiology / Anticoagulant Generic
Description

Generic anticoagulant equivalent to Bristol-Myers Squibb's Eliquis, available in 2.5mg and 5mg tablets for Germany and MENA markets. Used for the prevention and treatment of thromboembolic disorders.

6Simarax (Sildenafil 50mg)
CategoryUrology / Men's Health Generic Brand
Description

Macleods' UK brand for Sildenafil 50mg film-coated tablets indicated for erectile dysfunction. Marketed in the United Kingdom through Macleods Pharma UK Limited.

7Emtricitabine/Tenofovir Disoproxil Fumarate 200mg/245mg
CategoryAnti-Retroviral / HIV PrEP Generic
Description

Generic HIV medication equivalent to Gilead's Truvada, supplied as 200mg/245mg film-coated tablets for PrEP (pre-exposure prophylaxis) in the UK market through Macleods Pharma UK Limited.

8Antiretroviral therapy products (PT Sampharindo Retroviral Indonesia)
CategoryAnti-Retroviral / HIV Therapy
Description

Antiretroviral products developed and supplied through PT Sampharindo Retroviral Indonesia, a Macleods joint venture established in 2017 in Semarang, Central Java. Focused on developing new molecules for antiretroviral therapy and overcoming resistance challenges, including Abacavir, Atazanavir/Ritonavir, Lamivudine, Lopinavir/Ritonavir, Tenofovir, and Zidovudine formulations.

9Active Pharmaceutical Ingredients (APIs)
CategoryPharmaceutical Ingredients / APIs
Description

In-house manufactured Active Pharmaceutical Ingredients (APIs) developed by Macleods' R&D centres, transitioning from basic APIs to high-potency APIs and CDMO services under India's Production Linked Incentive (PLI) scheme. APIs support both Macleods' own formulations portfolio and contract supply.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Macleods Pharma completed projects under the Production Linked Incentive (PLI) scheme promoted by the Government of India to promote domestic manufacturing of pharmaceuticals. The company is transitioning from basic API manufacturing to high-potency APIs, CDMO services, and formulations as part of this initiative.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Torrent is an Indian mid-tier generic pharmaceutical manufacturer with strong presence in cardiovascular and CNS generics across India and emerging markets, similar therapeutic focus to Macleods.

2Sun Pharmaceutical Industries
TypeDirect peer
Description

Sun Pharma is India's largest pharmaceutical company and a vertically integrated generic and specialty pharma manufacturer with a comparable global footprint. It competes with Macleods in cardiovascular, CNS, and anti-infective generics across regulated and emerging markets.

TypeDirect peer
Description

Dr. Reddy's is a leading Indian generic pharmaceutical company with strong API and formulations businesses, significant US ANDA portfolio, and global distribution. It competes directly with Macleods in generic formulations across cardiovascular, CNS, and oncology categories.

TypeDirect peer
Description

Lupin is an Indian pharmaceutical company with comparable scale, a substantial US generics franchise, and API manufacturing capabilities. It overlaps with Macleods in cardiovascular, anti-TB, and other therapeutic generics across global markets.

TypeDirect peer
Description

Zydus is an Indian pharmaceutical company with vertically integrated API and formulations operations, including biosimilars, comparable to Macleods' integrated model. It competes in cardiovascular, anti-infectives, and other generics globally.

TypeDirect peer
Description

Aurobindo is a top-5 Indian generic pharmaceutical manufacturer with strong ARV, anti-infective, and US generics franchises. It competes with Macleods across therapeutic categories, particularly in ARVs and government/public health supply contracts.

TypeBroad incumbent
Description

Teva is the world's largest generic pharmaceutical manufacturer with extensive US and global operations. It competes with Macleods in cardiovascular, CNS, and anti-infective generics across regulated markets.

TypeDirect peer
Description

Cipla is a top-tier Indian generic pharmaceutical manufacturer with comparable global presence, strong anti-TB/ARV franchises, and USFDA-approved facilities. It directly competes with Macleods across therapeutic categories, geographies, and government supply programs, with overlapping leadership pedigrees (multiple Macleods SA executives came from Cipla).

9Sandoz (Novartis)
TypeBroad incumbent
Description

Sandoz is the global leader in generic pharmaceuticals, with a much larger global footprint and broader portfolio. It competes with Macleods in generic formulations across all major therapeutic categories and geographies.

TypeDirect peer
Description

Glenmark is an Indian generic and specialty pharmaceutical company with comparable India-anchored global operations. It overlaps with Macleods in respiratory, dermatology, and cardiovascular generics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Macleods Pharmaceuticals Ltd.

Generic Pharmaceuticalsmacleodspharma.com

Macleods Pharmaceuticals Ltd. is a privately held, vertically integrated Indian generic pharmaceutical company that develops, manufactures, and distributes medicines across 19+ therapeutic areas to public health programmes, hospitals, and pharmacies in 170+ countries through subsidiaries and out-licensing partners.

What Macleods Pharmaceuticals Ltd. does

Macleods Pharmaceuticals Ltd. is a privately held, vertically integrated Indian pharmaceutical company headquartered in Mumbai that develops, manufactures, and markets generic medicines across more than 19 therapeutic categories, including anti-tuberculosis drugs, antiretrovirals, anti-infectives, cardiovascular, central nervous system, diabetology, oncology, and peptides. The company operates its own active pharmaceutical ingredient (API) and formulations development facilities, supported by a 250-bed bioequivalence centre equipped with NABL-accredited clinical laboratories, 20 LC/MS/MS instruments, and SAS-based statistical analysis for crossover, replicate, parallel, and steady-state bioequivalence studies. Manufacturing facilities are inspected and approved by USFDA, WHO Geneva, UK MHRA, and ANVISA, with 185 ANDAs filed and 100 approved at the USFDA as of August 2023 and WHO prequalified medicines in the portfolio.

Macleods distributes products in over 170 countries through a mix of wholly-owned subsidiaries (USA, UK, Germany, Spain, South Africa, Ukraine, Kazakhstan, Malaysia, Philippines, and Nigeria), branch offices, a joint venture in Indonesia (PT Sampharindo Retroviral Indonesia, established 2017), and out-licensing arrangements with European distributors. Its customer base spans government health programmes such as India's National TB Elimination Programme and the Global Drug Facility, public healthcare systems, private hospitals and pharmacies, and institutional procurement channels. Direct field sales forces call on physicians, specialists, hospitals, and pharmacies across multiple markets, supplemented by participation in medical congresses and direct healthcare-professional communications.

Revenue is generated predominantly through one-time sales of generic pharmaceutical products across both regulated (US, UK, EU) and emerging (South Africa, MENA, CIS, Southeast Asia) markets, with pricing not publicly disclosed. The company has scaled through retained earnings rather than external funding, with 18,000+ employees globally. Notable recent strategic activity includes entry into the South Africa private sector (November 2022), a February 2026 Delhi High Court ruling favorable to Macleods in a Linagliptin patent challenge, and the appointment of a new group CFO in February 2026. The founder, Dr. Rajendra Agarwal, continues as Managing Director.

Macleods Pharmaceuticals Ltd. firmographics

Firmographics
Name
Macleods Pharmaceuticals Ltd.
Legal name
Macleods Pharmaceuticals Ltd.
Website
https://macleodspharma.com
Company type
Private
Founded year
1989
Operating status
Operating
Headcount range
10,001+ employees
Short description
Macleods Pharmaceuticals Ltd. is a privately held, vertically integrated Indian generic pharmaceutical company that develops, manufactures, and distributes medicines across 19+ therapeutic areas to public health programmes, hospitals, and pharmacies in 170+ countries through subsidiaries and out-licensing partners.
Ownership category
akta.pro rank

Macleods Pharmaceuticals Ltd. industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Generic pharmaceutical manufacturing
  • Active pharmaceutical ingredients
  • Bioequivalence studies
  • Antiretroviral medications
  • Anti-tuberculosis drugs

Where Macleods Pharmaceuticals Ltd. is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices10 records

Markets served

Macleods Pharmaceuticals Ltd. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Generic Pharmaceutical Products: Revenue generated from manufacturing and selling generic pharmaceutical formulations across multiple therapeutic categories including anti-TB, ARVs, cardiovascular, anti-infectives, CNS, diabetology, oncology, and other treatments. Products are sold in over 170 countries globally through direct presence in multiple markets.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Macleods Pharmaceuticals Ltd. product offering

Product offering

Core offering

Macleods Pharmaceuticals Ltd. is a vertically integrated global pharmaceutical manufacturer that develops, produces, and sells generic formulations and Active Pharmaceutical Ingredients (APIs) across more than 19 therapeutic categories including anti-tuberculosis, antiretrovirals, cardiovascular, central nervous system, diabetology, anti-infectives, anti-malarials, oncology, and peptides. The company operates R&D, bioanalytical and 250-bed bioequivalence centres, and manufactures products at facilities approved by USFDA, WHO Geneva, UK MHRA, and ANVISA, supplying generic medicines through direct subsidiaries, field sales, and out-licensing distributors in over 170 countries.

Product overview

Macleods Pharmaceuticals Ltd. is a vertically integrated global pharmaceutical organization and one of the top 10 companies in the Indian pharmaceutical market. The company provides generic pharmaceutical products across multiple therapeutic areas including Anti-Infectives, Anti-Virals, Anti-Retrovirals (ARVs), Blood Related, Cardiology, Central Nervous System, Diabetology, Endocrinology, Gastroenterology, Pain Management, Respiratory, Urology, Anti-Tuberculosis (Adult and Pediatric), Anti-Malaria, Oncology, and Peptides. The company operates R&D and bioequivalence centers with 250 beds, manufactures Active Pharmaceutical Ingredients (APIs) and formulations, and distributes products globally through subsidiaries and offices in India, USA, UK, Germany, Spain, South Africa, Kazakhstan, Ukraine, Indonesia, MENA region, and the Philippines. The product portfolio includes branded generics like Rivaroxaban, Apixaban, Simarax, and Emtricitabine/Tenofovir, as well as extensive generic formulations across all therapeutic categories.

Differentiator

Problem solved

Functional benefit

Brands

  • Simarax: Sildenafil 50 mg film-coated tablets for erectile dysfunction, marketed in the UK market.

Products and services

  • USA Generic Pharmaceutical Product Portfolio Generic pharmaceutical formulations distributed in the United States market across cardiovascular, central nervous system, anti-infective, and respiratory therapeutic categories, including products such as Acyclovir Ointment, Amlodipine/Olmesartan tablets, and Aripiprazole tablets. Marketed through Macleods Pharma USA Limited. As of August 31, 2023, Macleods had 185 ANDAs filed with USFDA, of which 100 were approved.
  • MENA Generic Pharmaceutical Product Portfolio Generic pharmaceutical products for Middle East and North Africa markets covering Anti-Infectives, Anti-Virals, Anti-Retrovirals, Blood Related, Cardiology, CNS, Diabetology, Endocrinology, Gastroenterology, Pain Management, Respiratory, Urology, Anti-Tuberculosis (Adult and Pediatric), Anti-Malaria, Oncology, and Peptides. Distributed through Macleods' MENA operations across Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Jordan, Lebanon, Syria, Israel, Egypt, and other regional markets.
  • Kazakhstan Generic Pharmaceutical Product Portfolio Products registered in Kazakhstan including Mucogen, Trimspa, Rabemac, Nupenta, Valmac, Clopi-75, Mucitus, Rapitus, and Zithrox-Macleods, spanning gastroenterology, cardiology, pulmonology, and infections. Distributed through Macleods Pharma Kazakhstan branch office with over 100 employees across major cities and regions.
  • Rivaroxaban generic anticoagulant Generic anticoagulant equivalent to Bayer's Xarelto, available in 2.5mg, 10mg, 15mg, and 20mg film-coated tablets for Germany and MENA markets. Used for the prevention and treatment of thromboembolic disorders.
  • Apixaban generic anticoagulant Generic anticoagulant equivalent to Bristol-Myers Squibb's Eliquis, available in 2.5mg and 5mg tablets for Germany and MENA markets. Used for the prevention and treatment of thromboembolic disorders.
  • Simarax (Sildenafil 50mg) Macleods' UK brand for Sildenafil 50mg film-coated tablets indicated for erectile dysfunction. Marketed in the United Kingdom through Macleods Pharma UK Limited.
  • Emtricitabine/Tenofovir Disoproxil Fumarate 200mg/245mg Generic HIV medication equivalent to Gilead's Truvada, supplied as 200mg/245mg film-coated tablets for PrEP (pre-exposure prophylaxis) in the UK market through Macleods Pharma UK Limited.
  • Antiretroviral therapy products (PT Sampharindo Retroviral Indonesia) Antiretroviral products developed and supplied through PT Sampharindo Retroviral Indonesia, a Macleods joint venture established in 2017 in Semarang, Central Java. Focused on developing new molecules for antiretroviral therapy and overcoming resistance challenges, including Abacavir, Atazanavir/Ritonavir, Lamivudine, Lopinavir/Ritonavir, Tenofovir, and Zidovudine formulations.
  • Active Pharmaceutical Ingredients (APIs) In-house manufactured Active Pharmaceutical Ingredients (APIs) developed by Macleods' R&D centres, transitioning from basic APIs to high-potency APIs and CDMO services under India's Production Linked Incentive (PLI) scheme. APIs support both Macleods' own formulations portfolio and contract supply.

Companies that use Macleods Pharmaceuticals Ltd.

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Macleods Pharmaceuticals Ltd. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Macleods Pharmaceuticals Ltd. partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Government of India (PLI Scheme)coreStrategic or Co-development PartnerMacleods Pharma completed projects under the Production Linked Incentive (PLI) scheme promoted by the Government of India to promote domestic manufacturing of pharmaceuticals. The company is transitioning from basic API manufacturing to high-potency APIs, CDMO services, and formulations as part of this initiative.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Macleods Pharmaceuticals Ltd. competitors and assessment

Company assessment

Direct peers

  • Torrent Pharmaceuticals: Torrent is an Indian mid-tier generic pharmaceutical manufacturer with strong presence in cardiovascular and CNS generics across India and emerging markets, similar therapeutic focus to Macleods.
  • Sun Pharmaceutical Industries: Sun Pharma is India's largest pharmaceutical company and a vertically integrated generic and specialty pharma manufacturer with a comparable global footprint. It competes with Macleods in cardiovascular, CNS, and anti-infective generics across regulated and emerging markets.
  • Dr. Reddy's Laboratories: Dr. Reddy's is a leading Indian generic pharmaceutical company with strong API and formulations businesses, significant US ANDA portfolio, and global distribution. It competes directly with Macleods in generic formulations across cardiovascular, CNS, and oncology categories.
  • Lupin Limited: Lupin is an Indian pharmaceutical company with comparable scale, a substantial US generics franchise, and API manufacturing capabilities. It overlaps with Macleods in cardiovascular, anti-TB, and other therapeutic generics across global markets.
  • Zydus Lifesciences: Zydus is an Indian pharmaceutical company with vertically integrated API and formulations operations, including biosimilars, comparable to Macleods' integrated model. It competes in cardiovascular, anti-infectives, and other generics globally.
  • Aurobindo Pharma: Aurobindo is a top-5 Indian generic pharmaceutical manufacturer with strong ARV, anti-infective, and US generics franchises. It competes with Macleods across therapeutic categories, particularly in ARVs and government/public health supply contracts.
  • Cipla Limited: Cipla is a top-tier Indian generic pharmaceutical manufacturer with comparable global presence, strong anti-TB/ARV franchises, and USFDA-approved facilities. It directly competes with Macleods across therapeutic categories, geographies, and government supply programs, with overlapping leadership pedigrees (multiple Macleods SA executives came from Cipla).
  • Glenmark Pharmaceuticals: Glenmark is an Indian generic and specialty pharmaceutical company with comparable India-anchored global operations. It overlaps with Macleods in respiratory, dermatology, and cardiovascular generics.

Broad incumbents

  • Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive US and global operations. It competes with Macleods in cardiovascular, CNS, and anti-infective generics across regulated markets.
  • Sandoz (Novartis): Sandoz is the global leader in generic pharmaceuticals, with a much larger global footprint and broader portfolio. It competes with Macleods in generic formulations across all major therapeutic categories and geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Macleods Pharmaceuticals Ltd. social profiles

Digital presence

Macleods Pharmaceuticals Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Macleods Pharmaceuticals Ltd. leadership team

Management profile

Number of profiles

Profiles8 records

Macleods Pharmaceuticals Ltd. subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

Macleods Pharmaceuticals Ltd. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Macleods Pharmaceuticals Ltd. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Macleods Pharmaceuticals Ltd.

What does Macleods Pharmaceuticals Ltd. do?

Macleods Pharmaceuticals Ltd. is a vertically integrated global pharmaceutical manufacturer that develops, produces, and sells generic formulations and Active Pharmaceutical Ingredients (APIs) across more than 19 therapeutic categories including anti-tuberculosis, antiretrovirals, cardiovascular, central nervous system, diabetology, anti-infectives, anti-malarials, oncology, and peptides. The company operates R&D, bioanalytical and 250-bed bioequivalence centres, and manufactures products at facilities approved by USFDA, WHO Geneva, UK MHRA, and ANVISA, supplying generic medicines through direct subsidiaries, field sales, and out-licensing distributors in over 170 countries.

Is Macleods Pharmaceuticals Ltd. a public or private company?

Macleods Pharmaceuticals Ltd. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Macleods Pharmaceuticals Ltd. founded?

Macleods Pharmaceuticals Ltd. was founded in 1989. It employs 10,001+ people.

Where is Macleods Pharmaceuticals Ltd. based?

Macleods Pharmaceuticals Ltd. is headquartered in Mumbai, India, in the Asia region.

How does Macleods Pharmaceuticals Ltd. make money?

One revenue line is on record: generic Pharmaceutical Products.

Who are Macleods Pharmaceuticals Ltd.'s main competitors?

Direct peers on record are Torrent Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences, Aurobindo Pharma, Cipla Limited and Glenmark Pharmaceuticals. Broad incumbents are Teva Pharmaceutical Industries and Sandoz (Novartis).

Does Macleods Pharmaceuticals Ltd. have an API?

No public API is recorded for Macleods Pharmaceuticals Ltd..

What industry is Macleods Pharmaceuticals Ltd. in?

Macleods Pharmaceuticals Ltd.'s product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAJAF, Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Providence JournalCheck your cabinet: Blood pressure medication recalled nationwideThe FDA recalled over 3,700 bottles of blood pressure medication nationwide. Macleods Pharmaceuticals recalled 30-count and 90-count bottles of its Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets on Oct. 7 due to failed dissolution specifications, meaning the medication may not release its active ingredients properly.YahooCheck your cabinet: Blood pressure medication recalled nationwideThe FDA recalled 3,700 bottles of Macleods Pharmaceuticals' blood pressure medication, including 30-count and 90-count versions, due to failed dissolution specifications. The Class II recall means use may cause temporary or reversible adverse effects but is unlikely to cause serious issues. Consumers are advised to consult a healthcare provider before making any decisions.The Straits TimesUS blood pressure drug recall does not affect Singapore: HSAHSA said the US recall of Macleods' blood pressure drug Tribenzor does not affect Singapore because the affected products are not sold here. The recall covers two lots after failed dissolution specifications raised concerns the medicine may not work properly. The US FDA classified it as a Class II recall, meaning possible temporary or medically reversible adverse health consequences.YahooTake blood pressure medicine? Check your cabinet for this nationwide recallMacleods Pharmaceuticals recalled over 3,700 bottles of blood pressure pills nationwide for failed dissolution specifications. The FDA rated the recall as Class II, meaning use may cause temporary or medically reversible adverse health consequences. Consumers are advised to consult their healthcare provider before making any decisions about their medication routine.Good HousekeepingFDA Announces Blood Pressure Medication Recall: What to Know NowThe FDA issued a Class II recall on October 26 for over 3,700 bottles of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets from Macleods Pharma USA. The tablets failed dissolution specifications, meaning they may not effectively lower blood pressure. Patients should verify lot numbers and contact their healthcare provider.YahooFDA Announces New Recall of Blood Pressure MedicationThe FDA issued a Class II recall on October 26 for over 3,700 bottles of blood pressure tablets from Macleods Pharma USA, initiated October 7. The recall covers two lots of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide due to failed dissolution specifications, which may reduce effectiveness. Patients are advised to contact their healthcare provider.YahooFDA elevates recall risk for blood pressure medicationThe FDA elevated the recall risk for a blood pressure medication to Class II on Oct. 26, affecting thousands of bottles of olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets from Macleods Pharma USA. The recall covers two lots with expiration dates of May 31, 2027, and consumers are advised to check their prescription bottles for affected lot numbers.YahooFDA Announces 3,700-Bottle Recall of Popular Blood Pressure MedicationThe FDA announced a voluntary recall of nearly 4,000 bottles of blood pressure medication by Macleods Pharma USA, initiated on October 7. The recall covers 3,528 30-count and 216 90-count bottles of olmesartan medoxomil, amlodipine, and hydrochlorothiazide, due to failure to meet dissolution specifications. The FDA classified it as Class II, meaning it may cause temporary or medically reversible adverse health consequences.PRESSBEEFDA Issues New Update on Blood Pressure Drug Recall Affecting Thousands of Bottles — Here’s Which Lots Are Affected ...Saudi ArabiaThe FDA issued a Class II recall on 3,744 bottles of Olmesartan, Amlodipine, and Hydrochlorothiazide tablets from Macleods Pharma USA, citing failed dissolution specifications. The affected lots expire May 31, 2027, and consumers are advised to check packaging and consult healthcare providers.YahooPopular blood pressure medication recalled over efficacy concernsMacleods Pharmaceuticals voluntarily recalled over 3,700 bottles of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets after the drug failed dissolution testing. The recall, designated Class II, covers 3,528 30-count and 216 90-count bottles distributed nationwide between Nov. 21, 2025, and April 27, 2026.